title: Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib.
abstract: This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial. Laboratory analysis of the peritoneal fluid showed no elevation of protein content and no evidence of underlying infection or tumor dissemination. This report highlights ascites as a previously unrecognized adverse reaction to sorafenib in a patient with a ventriculo-peritoneal shunt. We conclude that such patients should be closely monitored for this complication when treated with sorafenib.
authors.affiliation: Departments of *Pediatrics ∥Radiology, NYU Langone Medical Center, New York, NY Departments of †Pediatric Oncology §Neurosurgery, Boston Children's Hospital ‡Department of Pediatric Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA.
authors.forename: Geneviève
authors.initials: G
authors.lastname: Legault
authors.forename: Mark W
authors.initials: MW
authors.lastname: Kieran
authors.forename: Robert Michael
authors.initials: RM
authors.lastname: Scott
authors.forename: Christine
authors.initials: C
authors.lastname: Chordas
authors.forename: Sarah S
authors.initials: SS
authors.lastname: Milla
authors.forename: Matthias A
authors.initials: MA
authors.lastname: Karajannis
mesh_terms: D001201:Ascites / Q000139:chemically induced* / Q000473:pathology; D001254:Astrocytoma / Q000188:drug therapy*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D012008:Recurrence; D000077157:Sorafenib; D017287:Ventriculoperitoneal Shunt / Q000009:adverse effects*
chemical_list: D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D009536:Niacinamide; D000077157:Sorafenib